Table 4.

Univariate and multivariate survival analyses in relation to FXYD5 and clinicopathological parameters

	mRNA (high vs low)						Protein (score 2–3 vs score 1)
	OS			PFS			OS			PFS
Variables	HR	95% CI	p	HR	95% CI	p	HR	95% CI	p	HR	95% CI	p
Univariate analysis
FXYD5	2.09	1.19–3.69	0.011	1.97	1.16–3.33	0.012	2.57	1.24–5.32	0.011	2.18	1.15–4.139	0.017
Age (years)
≥65 vs <65	1.51	0.86–2.64	0.150	1.41	0.84–2.37	0.195	1.73	0.83–3.61	0.141	1.46	0.77–2.78	0.241
Menopausal status
Post vs Pre	1.41	0.68–2.90	0.353	1.68	0.82–3.43	0.154	1.61	0.62–4.19	0.329	1.61	0.67–3.84	0.286
FIGO stage
III and IV vs I and II	25.06	0–51–1221	0.104	3.93	0.95–16.23	0.059	25.89	0.31–21.87	0.151	3.81	0.91–15.99	0.067
Residual tumour (cm)
RT > 0 vs RT = 0	2.72	1.27–5.84	0.010	1.76	0.95–3.28	0.074	2.84	1.09–7.41	0.033	1.40	0.70–2.81	0.344
Lymphnodal involvement
Positive vs Negative	2.54	0.99–6.54	0.053	3.03	1.32–6.92	0.009	2.10	0.72–6.12	0.172	2.78	1.13–6.85	0.026
Peritoneal cytology
Positive vs Negative	26.55	0.77–919.5	0.070	5.09	1.23–21.16	0.025	27.96	0.48–16.34	0.109	5.14	1.21–21.78	0.026
Multivariate analysis
FXYD5	1.93	1.08–3.45	0.025	1.92	1.13–3.25	0.016	2.3	1.10–4.80	0.026	2.11	1.11–4.02	0.023
Age (years)	1.24	0.71–2.18	0.448	1.21	0.71–2.04	0.488	1.42	0.67–3.01	0.366	1.35	0.70–2.61	0.375
FIGO stage	0.74	0.45–1.21	0.226	0.99	0.63–1.55	0.951	0.88	0.48–1.60	0.665	1.05	0.64–1.71	0.852
Residual tumour	2.81	1.21–6.49	0.016	1.7	0.87–3.30	0.120	2.54	0.90–7.15	0.077	1.2	0.55–2.61	0.643

HR hazard ratio, CI confidence interval of the estimated HR

Bold type has been used for statistically significant results